A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

September 3, 2021

Study Completion Date

September 3, 2021

Conditions
Healthy
Interventions
DRUG

TP-03 (Lotilaner Ophthalmic Solution), 0.25%

A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.

Trial Locations (1)

Unknown

Altasciences, Mount Royal

All Listed Sponsors
lead

Tarsus Pharmaceuticals, Inc.

INDUSTRY

NCT05138861 - A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects | Biotech Hunter | Biotech Hunter